[CAS NO. 61177-45-5] Clavulanatepotassium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [61177-45-5]

Catalog

HY-A0256A

Brand

MCE

CAS

61177-45-5

DESCRIPTION [61177-45-5]

Overview

MDL	MFCD01710901
Molecular Weight	237.25
Molecular Formula	C8H8KNO5
SMILES	O=C([C@@H](/C(O[C@]1([H])C2)=C/CO)N1C2=O)O[K]

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Clavulanate potassium is a potent β-lactamase inhibitor and acts as an antibiotic ^[1] ^[2] .

IC50 & Target

β-lactamase ^[1]

In Vitro

Clavulanate potassium has weak antibacterial activity against most organisms when administered alone, but given in combination with beta-lactam antibiotics prevents antibiotic inactivation by microbial lactamase ^[1] .
Clavulanate potassium (0.25 mg/L, 0.5 mg/L) causes a relatively slow inhibition of growth, and a higher concentration (1 mg/L) is only marginally more effective than 0.5 mg/L ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00656747	Bayer	Chronic Bronchitis	March 2008	Phase 4
NCT04350502	Centre Hospitalier Universitaire, Amiens	Pleural Infection\|Empyema\|Community-acquired Pneumonia\|Pharmacokinetic\|Amoxicillin	April 4, 2020	Not Applicable
NCT02186951	University Hospital, Limoges	Ventilator-associated Pneumonia\|Cardiac Arrests With Shockable Rhythm\|Mild Therapeutic Hypothermia\|Preventive Antibiotics	August 18, 2014	Phase 3
NCT00917592	Consorci Sanitari de Terrassa\|Corporacion Parc Tauli	Diverticulitis	December 2005	Phase 4
NCT03809312	CHU de Quebec-Universite Laval	Chronic Sinus Infection	August 14, 2019	Phase 4
NCT02563769	Temple University\|National Institute on Drug Abuse (NIDA)\|University of Pennsylvania	Cocaine Dependence\|Cocaine Addiction\|Cocaine Abuse\|Cocaine-Related Disorders	September 2016	Phase 1
NCT05079620	UConn Health	Aspiration\|Aspiration Pneumonia	November 30, 2021	Phase 4
NCT00495586	Catalan Society of Family Medicine\|Fondo de Investigacion Sanitaria	Chronic Obstructive Pulmonary Disease	October 2007	Phase 4
NCT05562349	Temple University\|University of Pennsylvania Perelman School of Medicine\|Medical University of South Carolina\|Research Foundation for Mental Hygiene, Inc.	Cocaine Dependence	October 2022	Phase 2
NCT01015417	Centre Hospitalier Universitaire, Amiens	Acute Lithiasic Cholecystitis Grade I or II\|Symptoms Lasting for Less Than 5 Days\|Required Cholecystectomy\|Preoperative Amoxicillin Clavulanic Acid for at Most 5 Days	May 2010	Phase 3
NCT04980170	Jordan University Hospital	Antibiotics Causing Adverse Effects in Therapeutic Use	November 1, 2021	Early Phase 1
NCT02007603	Medical University of Vienna	Infection During Hemodialysis	August 2013	Phase 3
NCT03713424	University of Missouri-Columbia	Tobacco Use Disorder	March 26, 2019	Phase 2
NCT02571959	Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba	Obesity	July 24, 2015	Phase 1\|Phase 2
NCT00665873	Universita degli Studi di Catania	Infections	January 2004	Phase 4
NCT04400110	IRCCS Burlo Garofolo	Urinary Tract Infections	June 8, 2020	Phase 4
NCT03986762	Temple University\|National Institute on Drug Abuse (NIDA)	Cocaine Dependence, in Remission\|Cocaine Abuse, in Remission\|Cocaine-Related Disorders	March 12, 2019	Phase 1
NCT01096927	Maggiore Bellaria Hospital, Bologna	Lower Abdominal Pain\|Right Iliac Fossa Pain\|Acute Appendicitis	January 2010	Phase 4
NCT04411914	Temple University\|Beth Israel Deaconess Medical Center\|University of Pennsylvania Perelman School of Medicine	Cocaine Dependence	September 1, 2020	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 33.33 mg/mL ( 140.48 mM ; ultrasonic and adjust pH to 2 with HCl)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.2150 mL	21.0748 mL	42.1496 mL
5 mM	0.8430 mL	4.2150 mL	8.4299 mL
10 mM	0.4215 mL	2.1075 mL	4.2150 mL

* Please refer to the solubility information to select the appropriate solvent.

References

Synonyms

4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, potassium salt (1:1), (2R,3Z,5R)-

4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, monopotassium salt, [2R-(2α,3Z,5α)]-

4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, monopotassium salt, (2R,3Z,5R)-

Potassium clavulanate

BRL 14151K

Clavulanate potassium

Clavulanic acid potassium salt

Clavitesse

Serdaxin